Recent Finacing
Recent Raise
Opna Bio is a clinical-stage biopharma developing oncology, advancing an EPFL‑licensed FMRP program, Plexxikon‑acquired BET and CSF1R assets, and preclinical EP300, CD73, TEAD inhibitors targeting tumor immune suppression.
